2022 World Conference on Lung Cancer (ePosters)-EP02.04-003. A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases

EP02.04-003. A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases

Back to course

Pdf Summary

A study was conducted to compare the survival outcomes of patients with and without brain metastases who were treated with first-line Osimertinib, an oral tyrosine kinase inhibitor (TKI), for EGFR-positive non-small cell lung cancer (NSCLC). The study included a retrospective analysis of EGFR-mutant NSCLC patients in Alberta, Canada who were treated with Osimertinib between July 2018 and January 2021.<br /><br />The study found that there was no significant difference in treatment responses or outcomes between patients with and without brain metastases. The primary outcome of median overall survival (mOS) and secondary outcomes such as median time to treatment failure (mTTF), medical progression-free survival (mPFS), and objective response rate (ORR) did not differ significantly between the two groups.<br /><br />The study included 77 patients, of which 23% had brain metastases at the start of Osimertinib treatment. The demographic and clinical features of the two groups were comparable, although the group with brain metastases had a higher proportion of patients aged 70 years or older at diagnosis and a higher rate of brain radiation treatment.<br /><br />The results suggest that Osimertinib may be effective in treating both brain metastases and non-brain metastases in EGFR-mutated NSCLC patients. However, the small sample size of the study may have impacted the results, and further studies with larger populations are needed to confirm these findings.<br /><br />Overall, the study provides evidence that Osimertinib, with its ability to penetrate the blood-brain barrier, is a potential treatment option for EGFR-positive NSCLC patients with brain metastases. The study highlights the need for further research in this area to better understand the impact of Osimertinib on survival outcomes in this patient population.

Asset Subtitle

Ishjot Litt

Meta Tag

Speaker Ishjot Litt

Topic Early Stage Non-small Cell Lung Cancer - Systemic Therapy

Keywords

brain metastases

Osimertinib

tyrosine kinase inhibitor

EGFR-positive non-small cell lung cancer

survival outcomes

treatment responses

median overall survival

median time to treatment failure

medical progression-free survival

objective response rate